Cough Hypersensitivity in Patients With Metabolic Syndrome: A Clinical Finding and Its Possible Mechanisms

Jiafen Cheng
  Tongji University School of Medicine

Zhuangli Xie
  Tongji University School of Medicine

Shengyuan Wang
  Tongji University School of Medicine

Siwan Wen
  Tongji University School of Medicine

Shanshan Niu
  Tongji University School of Medicine

Cuiqin Shi
  Tongji University School of Medicine

Li Yu
  Tongji University School of Medicine

Xianghuai Xu (✉ 05849@tongji.edu.cn)
  Tongji University School of Medicine

Research Article

Keywords: metabolic syndrome, cough sensitivity, obstructive sleep apnea-hypopnea syndrome, gastroesophageal reflux disease, airway inflammation.

DOI: https://doi.org/10.21203/rs.3.rs-543329/v1

License: ☭ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose: To investigate the changes of cough sensitivity in patients with metabolic syndrome and its possible mechanisms.

Method: A total of 29 metabolic syndrome (MetS) patients with OSAHS (group-1), 22 MetS patients without OSAHS (group-2), and 25 healthy controls (group-3) were included. All participants underwent a routine physical examination and completed the gastroesophageal reflux disease questionnaire (GerdQ), and the inflammatory mediator profile were determined. The cough threshold for capsaicin, induced sputum cell count and cell classification, and inflammatory mediators in induced sputum supernatants were compared. The correlation between capsaicin cough sensitivity and various indicators in the MetS population was analyzed.

Results: The minimum concentration of inhaled capsaicin needed to induce ≥2 coughs (C2) was significantly different among three groups ($H = 13.856, P < 0.001$) and lower for group-1 and group-2 than it for group-3 ($P = 0.001, P = 0.003$), which was similar with the C5 concentrations (the minimum concentration of inhaled capsaicin needed to induce ≥5 coughs). The percentage of neutrophils in induced sputum and the concentrations of calcitonin gene-related peptide (CGRP), substance P (SP), and interleukin 8 (IL-8) in the sputum supernatant of group-1 and group-2 were significantly higher than those of group-3. Besides, the pepsin concentrations were significantly different among the 3 groups ($F = 129.362, P < 0.001$), which significantly was highest in group-1 ($P < 0.001$) and lowest in group-3 ($P < 0.001$). In group-1, lgC2 and lgC5 were both negatively correlated with the apnea-hypopnea index (AHI, $r = -0.577, P = 0.001; r = -0.394, P = 0.035$).

Conclusion: Increased capsaicin cough sensitivity in MetS patients is closely related to sleep apnea and gastroesophageal reflux. For patients in MetS patients without OSAHS, gastroesophageal reflux is an important factor for increased capsaicin cough sensitivity. Airway inflammation, especially airway neurogenic inflammation, may also play a role in the pathogenesis of increased capsaicin cough sensitivity.

Trial registration: The protocol was registered in the Chinese Clinical Trials Register (http://www.chictr.org.cn/) (ChiCTR1800014768). Written informed consent was obtained from all participants before enrollment.

Introduction

Chronic cough is defined as cough ≥ 8 weeks with a normal chest radiograph. Cough variant asthma, upper airway cough syndrome, eosinophilic bronchitis, and gastroesophageal reflux-induced cough are common etiologies of chronic cough [1, 2]; less common etiologies include obstructive sleep apnea-hypopnea syndrome (OSAHS) [3]. If following diagnosis and treatment procedures, cough can be controlled or alleviated in most patients [4]. However, 10%-42% of chronic cough patients cannot clarify
the etiology or receive effective treatment measures\(^5\), causing refractory or persistent cough. Therefore, rare etiologies must be continuously identified, which can effectively reduce the proportion of patients with refractory cough.

Many epidemiological studies have shown that obese patients have a higher risk of developing asthma than the general population, demonstrating that obesity is involved in the development of asthma\(^6\). Morales-Estrella et al. reported that patients with a higher BMI experience cough more often than other patients and that the cough is more severe in obese patients\(^7\), indicating that obese patients an increased susceptibility to cough. Recently, it was suggested that type 2 diabetes may be a risk factor for chronic cough and that self-reported chronic cough was more common in diabetic patients than in the general population\(^8\). Our previous research showed that OSAHS patients have a predisposition to cough hypersensitivity associated with airway inflammation\(^9\). Since obesity, type 2 diabetes and sleep apnea are all closely associated with chronic cough and bronchial asthma, metabolic syndrome (MetS) should be considered.

Because increased cough sensitivity is a common feature of all chronic cough patients, it is also called cough hypersensitivity syndrome\(^10,11\). We hypothesized that MetS patients had high cough sensitivity and were more vulnerable to coughing after receiving endogenous or exogenous coughing stimuli. This study tested the hypothesis by comparing the capsaicin cough sensitivity, induced sputum cell counts, and inflammatory mediators in induced sputum supernatants among MetS patients with OSAHS, MetS patients without OSAHS, and healthy control populations and explored the possible mechanisms underlying the increased capsaicin cough sensitivity in MetS patients.

### Materials And Methods

#### I. Participants:

1. MetS with OSAHS group: A total of 29 MetS patients diagnosed in the Department of Endocrinology and Metabolism at Tongji Hospital from December 2017 to May 2020 were included in this group. Moreover, these patients were diagnosed with OSAHS by polysomnography (PSG).

2. MetS without OSAHS group: A total of 22 MetS patients who were diagnosed in the Department of Endocrinology and Metabolism at Tongji Hospital from December 2017 to May 2020 were included in this group. In addition, these patients were included in this group, and did not meet OSAHS after being diagnosed by PSG.

Diagnostic criteria for MetS: MetS patients were diagnosed according to the “Chinese guidelines on the Prevention and Treatment of Dyslipidemia in Adults” revised in 2007 by the joint committee that developed the guidelines\(^12\): 1) abdominal obesity – waist circumference ≥ 90 cm for males and ≥ 85 cm for females; 2) hyperglycemia – fasting blood glucose ≥ 6.1 mmol/L or blood glucose ≥ 7.8 mmol/L 2 hours after glucose load and/or diagnosed with diabetes and subsequently treated; 3) hypertension – blood pressure ≥ 130/85 mmHg (1 mmHg = 0.133 kPa), and/or confirmed hypertension and receiving
treatment; 4) fasting triglyceride (TG) ≥ 1.70 mmol/L; and 5) fasting high-density lipoprotein cholesterol (HDL-C) < 1.04 mmol/L. Patients who meet 3 or more criteria can be diagnosed with MetS.

Diagnostic criteria for OSAHS: OSAHS was diagnosed according to the “International Classification of Sleep Disorders (3rd edition)” by the American Sleep Association (ICSD-3, 2014) [13].

3. Healthy control group: During the same period, 25 healthy volunteers without allergy were enrolled from the staff and medical students in the hospital and designated as healthy control group.

The inclusion criteria for the above participants were as follows: 1) between 18 and 65 years of age; 2) no wheezing, hemoptysis, and fever; 3) no obvious abnormalities on chest X-ray or CT; 4) pulmonary function tests: forced expiratory volume in one second (FEV₁) > 80% of predicted value, and FEV₁/forced vital capacity (FVC) > 70%; and normal airway reactivity; and 5) tolerable to cough sensitivity test to capsaicin and sputum induction. The exclusion criteria were as follows: 1) smoking history or smoking cessation < 2 years; 2) respiratory infections within 2 months; 3) pregnant or lactating women; 4) mental disorders; 5) The patients had no upper respiratory tract infection and no cough symptoms in the past 3 months. In addition, all participants with a history of chronic cough were also excluded.

The protocol was registered in the Chinese Clinical Trials Register (http://www.chictr.org.cn/) (ChiCTR1800014768). Written informed consent was obtained from all participants before enrollment.

II. Method

1. Capsaicin cough sensitivity test: According to an improved method by Department of Pulmonary and Critical Care Medicine at Tongji Hospital based on Fujimura’s established method [14, 15], participants inhaled a certain amount of capsaicin via aerosolization to induce coughing. The minimum concentrations of inhaled capsaicin that induced ≥ 2 or ≥ 5 coughs (cough thresholds C2 and C5) were indicators used to reflect cough sensitivity.

2. Epworth sleepiness scale (ESS): According to the ESS proposed by Johns [16], a total score < 5 points was defined as normal, 5-9 points was defined as mild sleepiness, 10-15 points was defined as moderate sleepiness, and 16-24 points was defined as severe sleepiness.

3. Gastroesophageal reflux disease questionnaire (GerdQ) [17]: The questionnaire comprises 6 symptom-related questions, of which 4 are questions related to symptoms positively correlated with reflux (A1, A2, C1, and C2) and the other 2 are questions related to symptoms negatively correlated with reflux (B1 and B2). The questionnaire asks respondents to recall the frequency of each symptom in the past week, and symptoms are divided into 4 levels according to degree. The score for each positive symptom increases with the increasing frequency of symptom onset. No positive symptoms appearing within the past week was set at 0 point; a positive symptom appearing 1 day within the past week was set at 1 point; a positive symptom appearing 2 to 3 days within the past week was set at 2 points; and a positive symptom appearing 4 to 7 days within the past week was
set at 3 points. The scoring criteria for negative symptoms were opposite, and the frequency grades were set as 3, 2, 1, and 0 points. The GerdQ score was the sum of scores for each symptom; the score ranged from 0 to 18 points, and a total score ≥ 8 points indicated the possibility of gastroesophageal reflux disease. The higher the score was, the higher the possibility.

4. Induced sputum cell counts: The analysis was conducted according to a method established by Department of Pulmonary and Critical Care Medicine at Tongji Hospital [18]. The participants inhaled 4% hypertonic saline by ultrasonic atomization for 20 min-30 min. The nasal cavity and mouth were cleaned every 5 min, deep coughing was performed to remove the phlegm in the lower lungs, and the first sputum containing saliva was discarded. Subsequent sputum samples were collected in sterile containers until obtaining 2 ml-3 ml and then stored. Dithiothreitol (0.1%, BBI, 4 times the volum of sputum) was added the sputum samples, and the samples were mixed by pipetting, and incubated in a 37 °C water bath for 10 min and vortexed for 10 min. The mixture was filtered through 48 µm nylon filter and centrifuged at 3000 r/min for 10 min. The supernatant was stored at -80 °C until use. The total number of cells in the induced sputum was counted using a hemocytometer. Cell viability was evaluated using trypan blue staining. The cell suspension was placed onto glass slides in a Shandon II cell centrifuge. The slides were air dried, and the samples were fixed with 4% paraformaldehyde and stained with hematoxylin–eosin (HE). Four hundred nucleated cells were counted under a microscope, and the percentages of macrophages, neutrophils, eosinophils, and lymphocytes were calculated.

5. Analysis of inflammatory mediators in induced sputum supernatants: The levels of bradykinin, calcitonin gene-related peptide (CGRP), substance P (SP), pepsin, prostaglandin E2 (PGE2), histamine, eosinophil cationic protein (ECP), and interleukin-8 (IL-8) in induced sputum supernatants were analyzed according to the kit instructions. The average value of 3 measurements was used as the final result. Each reagent kit was provided by Shanghai Yuanxiang Medical Devices Co. Ltd., imiproting from R & D Systems (United States). The error within the same detection batch was <5%, and the error among batches was <10%. The lower limit of detection for each mediator was as follows: bradykinin, 39.0 pg/ml; CGRP, 7.8 pg/ml; SP, 2.5 ng/ml; pepsin, 0.01 ng/ml; PGE2, 0.01 pg/ml; histamine, 0.78 ng/ml; ECP, 1.5 ng/ml, and IL-8, 7.8 pg/ml.

6. Measurement of basic parameters such as height, weight, waist circumference, and blood pressure: The basic parameters were measured by professionally trained medical personnel. Height was measured using a metal column sitting-height meter. The participants were barefoot and standing naturally upright, with their head facing forward, and their heels, sacrum and shoulder blades were in contact with the column. To read the data, the eyes of personnel responsible for recording the measurements were horizontal with the horizontal plate; height data were accurate to 0.1 cm. During the body weight measurement, participants were fasted, took off their shoes, and wore only light and thin clothes; body weight was accurate to 0.1 kg. Waist circumference was measured according to the method recommended by the World Health Organization (WHO). The participants were standing, with their feet 25 to 30 cm apart, allowing the even distribution of body weight. Circumference was measured in the horizontal plane midway between the lower edge of 12th rib and the superior border
of anterior superior iliac crest; the measuring tape was close to the soft tissue, and the data were accurate to 0.1 cm. Body mass index (BMI) = weight/height $^2$ (kg/m$^2$). Blood pressure was measured using a mercury sphygmomanometer. The measurement was performed twice at an interval of 5 min, and the average was taken.

7. Measurement of blood biochemical parameters: All subjects fasted for more than 10 hours, and fasting venous blood was drawn the morning of the next day. Triglycerides, HDL-C, and blood glucose were measured in our laboratory according to routine procedures.

8. Pulmonary function tests and exhaled nitric oxide measurement: These procedures were conducted by professional technicians. Pulmonary function tests were performed using a MasterScreen spirometer (Jaeger, Germany) according to the instructions. Exhaled nitric oxide measurements were performed according to the manufacturer's manual (NIOX, Sweden).

9. PSG monitoring: All night sleep monitoring was performed using Alice 5 Polysomnography (Philips Respironics, Inc.). Nose and mouth airflow, percutaneous oxygen saturation ($S_pO_2$), electroencephalography (EEG), eye movement, mandibular electromyography (EMG), chest and abdomen respiratory motion, posture, leg movements and snoring were recorded for at least 7 hours. After monitoring, the sleep physician (Dr. Shi) manually analyzed and normalized the data to calculate the apnea-hypopnea index (AHI, the average number of apneas or hypopneas recorded during the study per hour of sleep), minimum oxygen saturation during sleep, and mean oxygen saturation.

### III. Process

The enrolled participants first completed a basic medical history inquiry, had their body height and blood pressure recorded and underwent blood biochemical tests to establish a preliminary diagnosis of MetS; these procedures were followed by PSG monitoring, a pulmonary function test, an exhaled nitric oxide test, a capsaicin cough sensitivity test, and an induced sputum cell count. The remaining sputum was used for cytological analysis and an assay of the supernatant to determine the inflammatory mediator profile. Participants were subsequently divided into a MetS with OSAHS group and a MetS without OSAHS group based on PSG monitoring. The above tests were also completed in the healthy controls.

### IV. Statistical analysis

Data with a normal distribution are expressed as the mean ± SD, while those with a skewed distribution are expressed as the median (25% -75% interquartile). Moreover, C2 and C5 were log transformed to normalize the data and are presented as the geometric mean ± SD. Data among the 3 groups were analyzed using one-way analysis of variance (ANOVA) or a nonparametric test (Kruskal-Wallis H test). If there were differences among the groups, the LSD t-test or Mann-Whitney U test was used for pairwise comparisons between 2 groups. Correlation analyses were performed using Spearman's rank correlation
coefficient. Statistical analysis was performed with SPSS version 20.0 (a relatively newer version). \( P < 0.05 \) was considered statistically significant.

**Results**

1. General information, pulmonary function indicators and PSG monitoring results for the 3 groups

The general information, pulmonary function indicators, and PSG monitoring results for each group are provided in Table 1. There were no significant differences in sex distribution, age, neck circumference, pulmonary function indicators, exhaled nitric oxide, and history of rhinitis or gastric disease among the MetS with OSAHS group, the MetS without OSAHS group, and the healthy control group. Waist circumference, systolic pressure, diastolic pressure, triglycerides, high-density lipoprotein-cholesterol, and fasting blood glucose were significantly different among the 3 groups; these indicators were significantly higher in the MetS with OSAHS and MetS without OSAHS groups than those in the controls, meeting the diagnostic criteria for MetS. The AHI, minimum oxygen saturation, and average oxygen saturation were significantly different among the 3 groups, and the 3 indicators were significantly higher in the MetS with OSAHS group than in the MetS without OSAHS and the control groups, consistent with the diagnostic criteria for OSAHS. The BMI for the 3 groups was significantly different (\( F = 13.892, P = 0.000 \)). The BMI for the MetS with OSAHS group was significantly higher than that for the MetS without OSAHS and the control groups (\( P = 0.001, P = 0.000 \)). The GerdQ scores were significantly different among the 3 groups (\( F = 11.604, P = 0.000 \)) and were significantly higher in the MetS with OSAHS and the MetS without OSAHS groups than in the control group (\( P = 0.000, P = 0.007 \)). ESS scores were significantly different among the 3 groups (\( H = 19.985, P = 0.000 \)). The ESS score for the MetS with OSAHS group was higher than those for the MetS without OSAHS and control groups (\( P = 0.000, P = 0.000 \)).
Table 1
Comparison of the general data, pulmonary function indicators and PSG results among the groups.

| Variables                          | MetS with OSAHS | MetS without OSAHS | Healthy subjects |
|-----------------------------------|-----------------|--------------------|------------------|
| Case number (male)                | 29(18)          | 22(15)             | 25(13)           |
| Age                               | 42.3 ± 10.9     | 43.3 ± 9.5         | 38.0 ± 11.8      |
| BMI (kg/m²)                       | 27.2 ± 2.8#▲    | 24.3 ± 2.1         | 22.8 ± 1.9       |
| Neck circumference (cm)           | 41.6 ± 2.6      | 38.5 ± 3.4         | 38.6 ± 3.6       |
| Waist circumference (cm)          |                 |                    |                  |
| Male                              | 110.1 ± 12.1#   | 108.1 ± 10.1#      | 80.3 ± 2.8       |
| Female                            | 101.8 ± 8.3#    | 97.0 ± 7.2#        | 70.1 ± 9.8       |
| SBP (mmHg)                        | 152.9 ± 10.8#   | 151.8 ± 10.5#      | 124.2 ± 2.5      |
| DBP (mmHg)                        | 90.5 ± 6.4#     | 91.9 ± 6.2#        | 73.2 ± 8.3       |
| Triglyceride (mmol/L)             | 4.01 ± 1.51#    | 3.42 ± 0.92#       | 1.38 ± 0.23      |
| HDL-C (mmol/L)                    | 0.99 ± 0.03#    | 1.01 ± 0.04#       | 1.95 ± 0.05      |
| Fasting glucose (mmol/L)          | 7.5 ± 1.6#      | 8.2 ± 1.7#         | 5.3 ± 0.5        |
| GerdQ score (points)              | 9.1 ± 3.3#      | 8.7 ± 3.5#         | 6.1 ± 0.2        |
| ESS score (points)                | 9.0(4.0)#▲      | 3.5(2.0)           | 2(2.0)           |
| Cough symptom score               |                 |                    |                  |
| Daytime(points)                   | 0(0)            | 0(0)               | 0(0)             |
| Night-time(points)                | 0(0)            | 0(0)               | 0(0)             |
| FVC/predicted value %            | 90.2 ± 9.7      | 91.2 ± 10.4        | 92.2 ± 11.3      |
| FEV1/predicted value %            | 93.1 ± 11.1     | 94.3 ± 12.7        | 94.5 ± 8.6       |
| FEV1/FVC%                         | 82.7 ± 9.2      | 84.1 ± 9.9         | 83.9 ± 8.6       |
| FeNO (ppb)                        | 17.0(14.5)      | 16.0(11.0)         | 14.0(8.5)        |
| AH1 (times/h)                     | 36.5 ± 10.2#▲   | 6.2 ± 2.2          | 3.7 ± 1.6        |

Note: ▲ compared with the MetS without OSAHS group P < 0.05, # compared with the healthy control group P < 0.05.
Variables | MetS with OSAHS | MetS without OSAHS | Healthy subjects
--- | --- | --- | ---
Minimum oxygen saturation (%) | 65.7 ± 11.3#▲ | 84.1 ± 5.3 | 89.6 ± 3.2
Average oxygen saturation (%) | 81.2 ± 11.7#▲ | 91.5 ± 10.3 | 92.4 ± 8.9
Nephritis history (n,%) | 5(17.2) | 3(13.6) | 2(8.0)
History of gastric disease (n,%) | 8(27.6) | 5(18.2) | 3(12.0)

Note: ▲ compared with the MetS without OSAHS group P < 0.05, # compared with the healthy control group P < 0.05.

2. Comparison of capsaicin cough sensitivity among the groups

C2 was significantly different among the MetS with OSAHS, the MetS without OSAHS, and control groups (H = 13.8256, P = 0.000); it was significantly lower in the MetS with OSAHS and MetS without OSAHS groups than in the control group (P = 0.001, P = 0.003); however, there was no difference between the 2 MetS groups (P = 0.360). There was a significant difference in C5 among the 3 groups (H = 14.393, P = 0.001). The C5 concentrations for the MetS with OSAHS and MetS without OSAHS groups were significantly lower than that for the control group (P = 0.001, P = 0.001); however, there was no difference between the 2 MetS groups (P = 0.750). Similarly, the lgC2 and lgC5 for the MetS with OSAHS and MetS without OSAHS groups were lower than those for the control group. There was no difference in lgC2 and lgC5 between the MetS with OSAHS and the MetS without OSAHS groups (Table 2).

Table 2
Comparison of capsaicin cough sensitivity among the groups

| Variables   | MetS with OSAHS | MetS without OSAHS | Healthy subjects |
|-------------|----------------|--------------------|-----------------|
| C2 (µmol/L) | 1.95(2.92)#    | 2.93(2.92)#        | 7.80(11.70)     |
| C5 (µmol/L) | 7.80(13.65)#   | 7.80(11.70)#       | 15.60(15.60)    |
| lgC2        | 0.36 ± 0.09#   | 0.43 ± 0.09#       | 0.87 ± 0.10     |
| lgC5        | 0.82 ± 0.12#   | 0.86 ± 0.09#       | 1.35 ± 0.09     |

Note: # compared with the healthy control group P < 0.05.

3. Comparison of induced sputum cell counts and cell classification among the groups

There was no significant difference in the induced sputum cell counts, proportion of lymphocytes and proportion of eosinophils among the MetS with OSAHS, the MetS without OSAHS and control groups. There was a significant difference in the proportion of neutrophils among the 3 groups (H = 14.056, P = 0.001). The proportion of neutrophils in the MetS with OSAHS and MetS without OSAHS groups was...
significantly higher than that in the control group ($P = 0.004, P = 0.001$); however, there was no difference between the 2 MetS groups ($P = 0.168$, Fig. 2A). The proportion of macrophages were significantly different among the 3 groups ($H = 21.468, P = 0.000$) and significantly lower in the MetS with OSAHS and MetS without OSAHS groups than in the control group (healthy subjects) ($P = 0.000, P = 0.000$); however, there was no difference between the 2 MetS groups ($P = 0.372$, Fig. 2B).

4. Comparison of inflammatory mediators in the supernatant of induced sputum among the groups

The concentrations of bradykinin, PGE2, histamine, and ECP in the supernatant of induced sputum were not significantly different among the 3 groups. There was a significant difference in CGRP concentration among the 3 groups ($F = 17.697, P = 0.000$). The CGRP concentration in the MetS with OSAHS and MetS without OSAHS groups was significantly higher than that in the control group ($P = 0.000, P = 0.000$); however, there was no difference between the 2 MetS groups ($P = 0.346$). The SP concentration was significantly different among the 3 groups ($F = 5.892, P = 0.008$) and significantly higher in the MetS with OSAHS and MetS without OSAHS group than that in the control group ($P = 0.002, P = 0.038$); however, there was no difference between the 2 MetS groups ($P = 0.189$). There was a significant difference in IL-8 concentration among the 3 groups ($F = 14.340, P = 0.000$). IL-8 concentration was significantly higher in the MetS with OSAHS and MetS without OSAHS groups than that in the control group ($P = 0.000, P = 0.000$); however, there was no difference between the 2 MetS groups ($P = 0.779$). There was a significant difference in pepsin concentration among the 3 groups ($F = 129.362, P = 0.000$). The pepsin concentration in the MetS with OSAHS and MetS without OSAHS groups was significantly higher than that in the control group ($P = 0.000, P = 0.000$), and the pepsin concentration in the MetS with OSAHS group was significantly higher than that in the MetS without OSAHS group ($P = 0.000$, Table 3).
### Table 3
Comparison of inflammatory mediators in the supernatant of induced sputum among the groups

|                     | MetS with OSAHS   | MetS without OSAHS | Healthy subjects |
|---------------------|-------------------|--------------------|-----------------|
| Bradykinin (pg/mL)  | 153.52 ± 27.81    | 149.22 ± 23.95     | 133.63 ± 19.28  |
| CGRP (pg/ml)        | 33.67 ± 2.51#     | 36.50 ± 2.29#      | 19.75 ± 2.12    |
| SP (pg/mL)          | 42.30 ± 5.12#     | 38.18 ± 6.21#      | 31.33 ± 5.26    |
| Pepsin (ng/mL)      | 4.36 ± 0.85#▲     | 3.40 ± 0.69#       | 2.18 ± 0.43     |
| PGE$_2$ (pg/mL)     | 24.72 ± 5.32      | 22.85 ± 4.11       | 18.93 ± 4.83    |
| Histamine (ng/mL)   | 3.02 ± 0.45       | 2.86 ± 0.39        | 2.67 ± 0.26     |
| ECP (ng/ml)         | 5.51 ± 1.01       | 5.93 ± 1.12        | 5.08 ± 0.94     |
| IL-8 (pg/ml)        | 43.50 ± 7.22#     | 45.65 ± 6.87#      | 24.63 ± 3.66    |

**Note:** ▲ compared with the MetS without OSAHS group $P < 0.05$, # compared with the healthy control group $P < 0.05$.

5. Correlation analysis of capsaicin cough sensitivity and each indicator in the MetS population

The correlation between capsaicin cough sensitivity (lgC2 and lgC5) and various indicators in the MetS with OSAHS and MetS without OSAHS groups were analyzed. Spearman rank correlation analysis showed that in the MetS with OSAHS group, lgC2 was negatively correlated with the AHI ($r = -0.577, P = 0.001$, Fig. 3A); lgC5 was negatively correlated with the AHI ($r = -0.394, P = 0.035$, Fig. 3B); and lgC2 and lgC5 were not correlated with triglycerides, HDL-C, fasting blood glucose, bradykinin, CGRP, SP, pepsin, IL-8 and other indicators. In the MetS without OSAHS group, there was no correlation between lgC2 and lgC5 and the aforementioned indicators. In terms of exogenous factors, there was no correlation between lgC2 or lgC5 and waist circumference, blood pressure, GerdQ score, ESS score, neck circumference, history of past rhinitis, history of past gastritis, FeNO, lung function indicators, regardless of whether MetS patients had OSAHS or not.

**Discussion**

This study found that the capsaicin cough sensitivity was increased in MetS patients independent of the presence OSAHS, manifesting as a decreased cough threshold accompanied by an increased percentage of neutrophils in induced sputum and an increased concentration of IL-8, SP, CGRP and pepsin in the supernatant; additionally, the GerdQ scores for MetS patients was significantly higher than those for the control group. The caspase cough thresholds, lgC2 and lgC5, for the MetS with OSAHS group were significantly negatively correlated with the AHI, and the pepsin concentration in the MetS with OSAHS group was higher than that in the MetS without OSAHS group.
MetS is the general term for the presence of multiple clinical diseases, including obesity, hypertension, insulin resistance (or type 2 diabetes) and dyslipidemia. Data from China indicate that the prevalence of MetS among people over 60 years of age is 58.1%\cite{19}. With an increase in BMI, the prevalence of OSAHS also significantly increases; therefore, MetS is closely related to OSAHS\cite{20}. A study found that 33% of OSAHS patients had chronic cough, of which 28% had nighttime heartburn symptoms and 44% had rhinitis symptoms, suggesting that OSAHS-associated gastroesophageal reflux and postnasal drip may cause long-term cough\cite{21}. Our previous studies have also suggested that OSAHS patients have a high sensitivity to cough, manifesting as cough susceptibility\cite{9}. This study indicated that the capsaicin cough sensitivity of the MetS with OSAHS group was higher than that of the control group. The capsaicin cough sensitivity of the MetS with OSAHS group was negatively correlated with the AHI, suggesting that increased capsaicin cough sensitivity in MetS patients is closely related to OSAHS. The mechanism may be caused by airway inflammation, especially airway neurogenic inflammation and repeated airway obstruction\cite{9}. Gastroesophageal reflux is a common cause of chronic cough\cite{22,23}, and OSAHS patients have increased negative intrathoracic pressure during apnea, which induces or aggravates gastroesophageal reflux. Studies have found that nighttime reflux events in OSAHS patients are increased and that the incidence of nighttime reflux events is positively correlated with the AHI\cite{24}. In this study, the pepsin concentration in the MetS with OSAHS group was higher than that in the MetS without OSAHS group, indicating that in MetS patients, OSAHS may aggravate the severity of gastroesophageal reflux. The results of this study also indicated that history of rhinitis, ECP, and histamine were not significantly different among the 3 groups, suggesting that the increase in capsaicin cough sensitivity in MetS patients was not significantly related to rhinitis.

Our study also found that the capsaicin cough sensitivity of patients with MetS without OSAHS significantly increased, indicating that increased cough sensitivity in MetS patients was not simply caused by the presence of OSAHS. The pepsin concentration and the GerdQ score in the MetS without OSAHS group were significantly higher than those in the control group, suggesting that gastrointestinal reflux is an important factor for the increase in capsaicin cough sensitivity in MetS patients without OSAHS. Why did these patients also have gastroesophageal reflux? First, hypertriglyceridemia is a risk factor for gastroesophageal reflux\cite{25–28}. The probable reason is that the lower esophageal sphincter pressure and the autonomic contraction frequency in the lower esophagus are affected by elevated blood lipid levels, leading to the abnormal secretion of gastrointestinal hormones and an increase in low-density lipoproteins, subsequently inducing gastroesophageal reflux. Second, high blood glucose levels can cause autonomic neuropathy, which in turn affects esophageal motility and gastrointestinal emptying. In patients with diabetes, esophageal motility is reduced, peristaltic waves are reduced or absent, reverse peristalsis can occur, and gastroesophageal reflux-related symptoms are present\cite{29,30}. In addition, hypertension and gastroesophageal reflux have many common risk factors, such as age, obesity, smoking, and drinking\cite{28,31,32}. However, the specific mechanism is still not clear. The mechanism of chronic cough caused by gastroesophageal reflux includes the theory of reflux and the theory of reflex. The former proposes that reflux of the stomach contents into the gullet or trace amounts of aspiration
into the lungs can stimulate the throat or trachea and tracheobronchial cough receptor to cause coughing. The latter proposes that esophageal stimuli generated by lower esophageal reflux induce airway neurogenic inflammation through an esophageal-bronchial reflex and stimulate coughing centers or a sensitize cough reflex to cause coughing. MetS without OSAHS group did not have hypopnea or apnea, and their AHI was normal, so there was no correlation between IgC2, IgC5 and AHI in this group.

This study found that neutrophilic inflammation exists in the lower airway of MetS patients. Taking into account the steps for cleaning the nasal cavity and mouth during the induction process, the possibility of contamination of nasopharyngeal inflammatory secretions in sputum is relatively low. Therefore, the neutrophils in the induced sputum are mainly from the lower airway. The patients in the MetS group did not have infection-related manifestations, such as fever and jaundice. Therefore, neutrophilic airway inflammation was not caused by infection. Coughing itself can cause mechanical injuries to the airway mucosa, and related studies in a guinea pig cough model, including those by our group, also showed that coughing can cause airway damage, produce neutrophilic airway inflammation, and increase the hypersensitivity of the cough reflex \cite{33,34}. Activated neutrophils can secrete neutrophil elastase (NE) to further promote the release of IL-8 from epithelial cells. In this study, the increase in IL-8 concentration in the supernatant of induced sputum from MetS patients also provided evidence of neutrophilic airway inflammation. In addition, neutrophil metabolism is related to the expression of receptor for advanced glycation end products (RAGE) \cite{35,36}. RAGE is a cell membrane surface protein. After binding with the corresponding ligands, RAGE upregulates the synthesis and secretion of IL-8 and promotes the local infiltration of neutrophils. Furthermore, it inhibits the phagocytosis of apoptotic neutrophils by phagocytic cells, directly leading to the release of antigenic substances in apoptotic cells, thereby aggravating the local inflammatory response \cite{37,38}. Further studies need to be conducted to confirm the upregulation of RAGE expression in the lower airway of MetS patients, which results in an increase in the proportion of neutrophils. The classical mechanism of cough hypersensitivity involves the inflammatory-mediator activation of TRPV1, which stimulates the vagal afferent terminals, resulting in neurogenic airway inflammation, leading to the release of neuropeptides such as SP and CGRP which stimulates local nerves as well as transmitting signals to the central nervous system, thereby increasing cough sensitivity \cite{39}. The results of this study showed that the concentrations of SP and CGRP in the supernatant of induced sputum from MetS patients significantly increased, further indicating that airway inflammation, especially neurogenic airway inflammation, plays an important role in the cough hypersensitivity of MetS patients.

This study has some limitations. First, induced sputum from MetS patients was not retested after treatment to further confirm the causal relationship between neutrophilic airway inflammation and cough. Second, all participants did not receive multichannel intraluminal impedance combined with pH monitoring (MII). The specific reflux property and severity were not clear, but we explored the pepsin concentration in the induced sputum supernatant and the GerdQ score and evaluated gastroesophageal reflux from the aspects of objective detection and subjective evaluation. Third, related inspections for cough susceptibility, including cough induced by inhalation of capsaicin, induced sputum testing, lung
function, FeNO, PSG monitoring, are not routine examination items for patients with metabolic syndrome, leading to difficulties in inclusion and insufficient sample size. We will continue to expand the sample size and conduct further research.

In summary, MetS patients are susceptible to cough. Increased capsaicin cough sensitivity in these patients is closely related to sleep apnea and gastroesophageal reflux. In MetS patients without OSAHS, gastroesophageal reflux is an important factor that increases capsaicin cough sensitivity. Airway inflammation, especially airway neurogenic inflammation, may play a role in increased capsaicin cough sensitivity in MetS patients.

Declarations

Ethics approval and consent to participate

The protocol was approved by the Ethics Committee of Tongji Hospital (2018-LCYJ-013). The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This study was supported by the National Natural Science Foundation of China (No. 81770097 and 82070102), the Project of Science and Technology Commission of Shanghai Municipality (No. 17411970800 and 20ZR1451500), the Fund of Shanghai Municipal Health Commission for Excellent Young Scholars (No. 2018YQ01), the Fund of Shanghai Youth Talent Support Program and the Shanghai Sailing Program (No. 19YF1444100).

Authors’ contributions

(I) Conception and design: JC, ZX, SW, XX, LY

(II) Administrative support: LY
(III) Provision of study materials or patients: JC, ZX, SW, SW, CS, ZQ, XX, LY

(IV) Collection and assembly of data: JC, ZX, SW, SW, SN, ZQ, XX, LY

(V) Data analysis and interpretation: JC, ZX, SW

(VI) Manuscript writing: All authors

(VII) Final approval of manuscript: All authors

Acknowledgements

Not applicable

References

1. Ding H, Xu X, Wen S, Yu Y, Pan J, Shi C, Dong R, Qiu Z, Yu L. Changing etiological frequency of chronic cough in a tertiary hospital in Shanghai, China. Journal of thoracic disease. 2019; 11; 3482–3489.

2. Yu Y, Wen S, Wang S, Shi C, Ding H, Qiu Z, Xu X, Yu L. Reflux characteristics in patients with gastroesophageal reflux-related chronic cough complicated by laryngopharyngeal reflux. Annals of translational medicine. 2019; 7; 529.

3. Sundar KM, Daly SE. Chronic cough and OSA: an underappreciated relationship. Lung. 2014; 192; 21–25.

4. Group CMAoRDAS. Guidelines for the diagnosis and treatment of coughing (2015). Zhonghua jiehe he huxi zazhi. 2016; 039; 323–354.

5. French CL, Crawford SL, Bova C, Irwin RS. Change in Psychological, Physiological, and Situational Factors in Adults After Treatment of Chronic Cough. Chest. 2017; 152; 547–562.

6. Telenga ED, Tideman SW, Kerstjens HA, Hacken NH, Timens W, Postma DS, van den Berge M. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy. 2012; 67; 1060–1068.

7. Morales-Estrella JL, Ciftci FD, Trick WE, Hinami K. Physical symptoms screening for cardiopulmonary complications of obesity using audio computer-assisted self-interviews. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation. 2017; 26; 2085–2092.

8. De Santi F, Zoppini G, Locatelli F, Finocchio E, Cappa V, Dauriz M, Verlato G. Type 2 diabetes is associated with an increased prevalence of respiratory symptoms as compared to the general population. BMC Pulm Med. 2017; 17; 101.

9. Shi C, Liang S, Xu X, Chen Q, Wang L, Yu L, Lv H, Qiu Z. Cough hypersensitivity in patients with obstructive sleep apnea hypopnea syndrome. Sleep Breath. 2019; 23; 33–39.
10. Morice AH. The cough hypersensitivity syndrome: a novel paradigm for understanding cough. Lung.2010; 188 Suppl 1;S87-90.
11. Song WJ, Morice AH. Cough Hypersensitivity Syndrome: A Few More Steps Forward. Allergy, asthma & immunology research.2017; 9;394–402.
12. China JCotDoGftPaToDi. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults. Zhonghua Xin Xue Guan Bing Za Zhi.2007; 35;390–419.
13. Sateia MJ. International Classification of Sleep Disorders-Third Edition. Chest.2014; 146;1387–1394.
14. Yu L, Xu X, Wang L, Yang Z, Lü H, Qiu Z. Capsaicin-sensitive cough receptors in lower airway are responsible for cough hypersensitivity in patients with upper airway cough syndrome. Med Sci Monit.2013; 19;1095–1101.
15. Fujimura M, Kasahara K, Kamio Y, Naruse M, Hashimoto T, Matsuda T. Female gender as a determinant of cough threshold to inhaled capsaicin. Eur Respir J.1996; 9;1624–1626.
16. Johns MW. A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. Sleep.1991; 14;540–545.
17. Xu X, Chen Q, Liang S, Lv H, Qiu Z. Comparison of gastroesophageal reflux disease questionnaire and multichannel intraluminal impedance pH monitoring in identifying patients with chronic cough responsive to antireflux therapy. Chest.2014; 145;1264–1270.
18. Yu L, Xu XH, Chen Q, Liang SW, Lv HJ, Qiu ZM. Gastro-esophageal reflux induced cough with airway hyperresponsiveness. International journal of clinical and experimental medicine.2014; 7;728–735.
19. Liu M, Wang J, Jiang B, Sun D, Wu L, Yang S, Wang Y, Li X, He Y. Increasing Prevalence of Metabolic Syndrome in a Chinese Elderly Population: 2001–2010. PLoS ONE.2013; 8;e66233.
20. Tażbirek M, Potoczny J, Strójwas K, Pierzchała W, Barczyk A. Anthropometric Factors in the Assessment of Obstructive Sleep Apnea Risk in Patients with Metabolic Syndrome. Advances in experimental medicine and biology.2019; 1160;35–41.
21. Chan KK, Ing AJ, Laks L, Cossa G, Rogers P, Birring SS. Chronic cough in patients with sleep-disordered breathing. Eur Respir J.2010; 35;368–372.
22. Xu X, Lv H, Yu L, Chen Q, Liang S, Qiu Z. A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough. Journal of thoracic disease.2016; 8;178–185.
23. Xu X, Yang Z, Chen Q, Yu L, Liang S, Lü H, Qiu Z. Comparison of clinical characteristics of chronic cough due to non-acid and acid gastroesophageal reflux. The clinical respiratory journal.2015; 9;196–202.
24. Shepherd KL, James AL, Musk AW, Hunter ML, Hillman DR, Eastwood PR. Gastro-oesophageal reflux symptoms are related to the presence and severity of obstructive sleep apnoea. Journal of sleep research.2011; 20;241–249.
25. Loke SS, Yang KD, Chen KD, Chen JF. Erosive esophagitis associated with metabolic syndrome, impaired liver function, and dyslipidemia. World journal of gastroenterology.2013; 19;5883–5888.
26. Chung SJ, Kim D, Park MJ, Kim YS, Kim JS, Jung HC, Song IS. Metabolic syndrome and visceral obesity as risk factors for reflux oesophagitis: a cross-sectional case-control study of 7078 Koreans undergoing health check-ups. Gut. 2008; 57;1360–1365.

27. Hsu CS, Wang PC, Chen JH, Su WC, Tseng TC, Chen HD, Hsiao TH, Wang CC, Lin HH, Shyu RY et al. Increasing insulin resistance is associated with increased severity and prevalence of gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics. 2011; 34;994–1004.

28. Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. Is Atrial Fibrillation a Risk Factor for Gastroesophageal Reflux Disease Occurrence? Medicine. 2015; 94;e1921.

29. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of internal medicine. 2005; 143;199–211.

30. Hsieh YH, Wu MF, Yang PY, Liao WC, Hsieh YH, Chang YJ, Lin IC. What is the impact of metabolic syndrome and its components on reflux esophagitis? A cross-sectional study. BMC gastroenterology. 2019; 19;33.

31. Chua CS, Lin YM, Yu FC, Hsu YH, Chen JH, Yang KC, Shi Ch. Metabolic risk factors associated with erosive esophagitis. Journal of gastroenterology and hepatology. 2009; 24;1375–1379.

32. Lee SW, Lien HC, Chang CS, Lee TY, Peng YC, Yeh HZ. Association of metabolic syndrome with erosive esophagitis and Barrett’s esophagus in a Chinese population. Journal of the Chinese Medical Association: JCMA. 2017; 80;15–18.

33. Xu X, Chen Q, Qiu Z, Shi C, Ding H, Wang L, Lv H, Yu L. Association of cough hypersensitivity with tracheal TRPV1 activation and neurogenic inflammation in a novel guinea pig model of citric acid-induced chronic cough. J Int Med Res. 2018; 46;2913–2924.

34. Hara J, Fujimura M, Ueda A, Myou S, Oribe Y, Ohkura N, Kita T, Yasui M, Kasahara K. Effect of pressure stress applied to the airway on cough-reflex sensitivity in Guinea pigs. Am J Respir Crit Care Med. 2008; 177;585–592.

35. Huebener P, Pradere JP, Hernandez C, Gwak GY, Caviglia JM, Mu X, Loike JD, Jenkins RE, Antoine DJ, Schwabe RF. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. The Journal of clinical investigation. 2019; 130;1802.

36. Tadié JM, Bae HB, Banerjee S, Zmijewski JW, Abraham E. Differential activation of RAGE by HMGB1 modulates neutrophil-associated NADPH oxidase activity and bacterial killing. American journal of physiology Cell physiology. 2012; 302;C249–256.

37. Wang H, Wang T, Yuan Z, Cao Y, Zhou Y, He J, Shen Y, Zeng N, Dai L, Wen F et al. Role of Receptor for Advanced Glycation End Products in Regulating Lung Fluid Balance in Lipopolysaccharide-induced Acute Lung Injury and Infection-Related Acute Respiratory Distress Syndrome. Shock (Augusta, Ga). 2018; 50;472–482.

38. He M, Kubo H, Morimoto K, Fujino N, Suzuki T, Takahasi T, Yamada M, Yamaya M, Maekawa T, Yamamoto Y et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep. 2011; 12;358–364.
39. Lv H, Yue J, Chen Z, Chai S, Cao X, Zhan J, Ji Z, Zhang H, Dong R, Lai K. Effect of transient receptor potential vanilloid-1 on cough hypersensitivity induced by particulate matter 2.5. Life sciences. 2016; 151; 157–166.

Figures

Figure 1
The inclusion process of the three groups of participants of MetS with OSAHS, MetS without OSAHS and healthy control group.

Figure 2

The proportion of neutrophils (A) and macrophages (B) in induced sputum.

Figure 3

Correlation between IgC2 (A) and IgC5 (B) and the AHI in the MetS with OSAHS group.